SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Rossari Biotech reports 19% rise in Q1 consolidated net profit

22 Jul 2024 Evaluate

Rossari Biotech has reported results for first quarter ended June 30, 2024 (Q1FY25). 

The company has reported 12.85% rise in its net profit at Rs 24.33 crore for the quarter ended June 30, 2024 as compared to Rs 21.56 crore for the same quarter in the previous year. Total income of the company increased by 16.28% at Rs 301.97 crore for Q1FY25 as compared to Rs 259.68 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 19.43% rise in net profit at Rs 34.90 crore for Q1FY25 as compared to Rs 29.22 crore for the same quarter in the previous year. Total income of the company increased by 18.84% at Rs 490.60 crore for Q1FY25 as compared to Rs 412.80 crore for the corresponding quarter previous year.

Rossari Biotech Share Price

480.90 2.15 (0.45%)
04-May-2026 12:41 View Price Chart
Peers
Company Name CMP
BASF India 3689.95
Tata Chemicals 814.40
SRF 2559.10
Pidilite Inds. 1375.05
Deepak Nitrite 1753.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×